<DOC>
	<DOCNO>NCT00838591</DOCNO>
	<brief_summary>The objective clinical study examine safety effectiveness intravenous MN-221 compare placebo administer adjunct standard therapy subject experience acute exacerbation asthma .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy MN-221 Adjunct Standard Therapy Subjects Experiencing Acute Exacerbation Asthma</brief_title>
	<detailed_description>This international , randomize , double-blind , placebo-controlled , multi-center ED study . Each subject receive MN-221 placebo administer continuous intravenous infusion addition standardize treatment acute exacerbation asthma . Upon presentation ED assessment treatment acute exacerbation asthma patient receive standard care consistent international guideline ( e.g. , Global Initiative Asthma [ GINA ] National Asthma Education Prevention Program [ NAEPP ] ) require , part , protocol prior screen procedure perform . Prior study specific treatment evaluation perform subject must sign IRB/EC/REB approve consent form . Once subject receive initial treatment regimen subject assess response treatment include spirometry.If subject meet entry criterion subject randomize receive MN-221 placebo . Throughout screen process subject continue receive standardize treatment consistent appropriate guideline treatment acute exacerbation asthma . Subjects enrol study receive intravenous 1-hour infusion MN-221 study drug placebo . Subjects receive MN-221 administer total dose 1200 μg . During study treatment period , subject may continue receive standardized treatment assess . The study treatment period approximately 3 hour length . Safety efficacy monitor throughout treatment period . PK parameter ( applicable ) obtain subject select study site . A blood sample genomic evaluation collect treatment period ( participate site ) subject consent evaluation . An initial 24-hour post-randomization follow-up visit complete evaluate subject 's health status well safety PK parameter ( applicable ) . A second follow-up contact complete telephone seven day post-randomization safety purpose evaluate subject 's health status . A periodic risk/benefit evaluation perform study 's Data Safety Monitoring Board .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Subjects meet follow criterion consider admission study : 1 . Male female 18 65 year age , inclusive ; 2 . Selfreported history physiciandiagnosed treat asthma ≥ 3 month prior randomization ; 3 . A diagnosis acute exacerbation asthma upon presentation ED define dyspnea evidence bronchospasm ; 4 . Received follow Standardized Treatment within 2hour time window prior obtain Qualifying Spirometry value ( FEV1 ) : Supplemental oxygen give maintain oxygen saturation measure pulse oximetry ≥ 90 % need ; Albuterol 515mg albuterol via nebulizer prior qualify spirometry evaluation ; simultaneously Ipratropium 0.51.5 mg ipratropium via nebulizer prior qualify spirometry evaluation ; One dose corticosteroid least 50 mg give orally ( prednisone ) intravenously ( methylprednisolone ) equivalent dose another corticosteroid . 5 . FEV1 ≤ 50 % predict ; NOTE : Spirometry measure subject 's FEV1 express % predict within 30 minute complete administration 5 mg ( 15 mg ) albuterol 0.5 mg ( 1.5 mg ) ipratropium.. 6 . Negative urine pregnancy test female childbearing potential ; 7 . ECG dysrhythmias ( except sinus tachycardia ) ; 8 . No clinical electrocardiographic sign ischemic heart disease determine Investigator ; 9 . Legally effective write informed consent obtain prior start mandate study procedure Subjects exclude meet follow criterion : 1 . Administration parenteral ( intravenous subcutaneous ) beta agonist ( e. g. , albuterol , terbutaline , epinephrine ) within 6 hour prior randomization ; 2 . A current prior diagnosis suspect diagnosis COPD chronic lung disease asthma ; 3 . Presence pneumonia ; 4 . Presence significant respiratory dysfunction pneumothorax , pneumomediastinum , pulmonary edema ; 5 . Known suspected vocal cord dysfunction syndrome ; 6 . Presence aspirate foreign body ( know suspect ) ; 7 . History current clinical evidence suggest cardiomyopathy congestive heart failure ; 8 . History presence tachyarrhythmias , exception sinus tachycardia ; 9 . Heart rate ≥ 140 bpm ; 10 . Hypokalemia , define subject serum potassium level &lt; 2.8 mEq/L ( ≤2.8 mmol/L ) obtain Screening ( local stat lab , blood gas analysis , point care device ) follow exception : For subject use nonpotassiumsparing diuretic ( i.e . loopdiuretic thiazide diuretic ) without `` potassiumsparing diuretic '' ( e.g. , Triamterene Spironolactone ) OR without potassium supplementation least KCl 20 mEq/day whose potassium level &lt; 3.5 mEq/L ( &lt; 3.5 mmol/L ) Screening . 11 . Significant cardiac , renal , hepatic , endocrine , metabolic , neurologic systemic disease . A significant disease define one , opinion Investigator , may either put subject risk participation study , may influence result study subject 's ability participate trial ; 12 . Selfreported history great 20 packyr smoke history ; 13 . Fever ≥ 102.0 ºF ( 38.9 ºC ) ; 14 . Uncontrolled hypertension define blood pressure ≥ 170/100 mm Hg ( 22.7/13.3 kPa ) ; 15 . Need immediate intubation , mechanical ventilation , noninvasive positive pressure ventilation determine Investigator ; 16 . Pregnant lactating female ; 17 . Participated another clinical study investigational drug within 30 day randomization ; 18 . Positive urine drug screen cocaine , methamphetamine PCP unless , Investigator 's clinical judgment , single positive result explain exposure nonillicit drug product ( i.e. , false positive ) . For example , phenylpropanolamine methylphenidate may read positive methamphetamine screen ; dextromethorphan PCP screen . 19 . Any subject know allergy component MN221 drug product ; 20 . Any subject know allergy beta agonist ; 21 . Previous exposure MN221 ; 22 . Use theophylline , beta blocker , digoxin , MAO inhibitor , tricyclic antidepressant within 2 week prior randomization . Use nonpotassiumsparing diuretic ( i.e . Thiazide Loopdiuretic ) without potassiumsparing diuretic OR without potassium supplementation &gt; 20 mEq/day within 2 week prior randomization serum potassium level Screening &lt; 3.5 mEq/L ( &lt; 3.5 mmol/L ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>MN-221</keyword>
	<keyword>Asthma</keyword>
	<keyword>Acute</keyword>
	<keyword>Exacerbation</keyword>
</DOC>